Supply Chain

Insmed, a Bridgewater, N.J.-based drugmaker focusing on treatments for rare diseases, purchased the exclusive global rights to AstraZeneca's experimental respiratory drug AZD7986.

Novartis will close research operations in Switzerland and China, resulting in 175 job cuts, reports Reuters. The move represents an effort to lower costs and centralize control over the Basel, Switzerland-based company's drug development programs.

The House Oversight and Government Reform Committee is undeterred from its quest at uncovering exactly how much profit Canonsburg, Pa.-based Mylan makes on its EpiPen sales.

Datwyler, an Altdorf, Switzerland-based industrial supplier, will construct a $102 million manufacturing plant in Delaware.

With the healthcare industry moving more and more toward pay-for-performance models, high-quality patient care is more important than ever. Hospitals must manage efficient inventory systems so nurses and physicians can shift their attention away from the stock rooms to what's…

With Hurricane Matthew scheduled to hit the East Coast later this week, Jacksonville, Fla.-based hospitals are readying supplies and reviewing emergency action plans, according to News4jax.

The Food and Drug Administration has approved 17 new drugs in 2016, with several regulatory decisions set to be made in October, according to Zacks Investment Research.

The United States Drug Enforcement Administration reduced the number of almost every opioid medication approved for manufacturing in 2017 by 25 percent or more.

New Brunswick, N.J.-based Johnson & Johnson identified a low-risk security issue in one of its insulin pumps that could allow hackers to overdose diabetic patients with insulin, reported Reuters.

Cambridge, Mass.-based Sarepta Therapeutics recently entered into a licensing and collaboration agreement with Abingdon, U.K.-based Summit Therapeutics.